secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-05-18T13:01:28+00:00
Accession:  0001104659-26-063059
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia announces three late-breaking abstracts accepted for ADA 2026 poster presentations
--------------------------------------------------------------------------------

- DA-1726 (GLP-1/glucagon dual agonist) Phase 1 Part 3 titration study data expected Q4 2026.
- Vanoglipel (GPR119 agonist) preclinical combo data with resmetirom for MASH and metformin for T2D.
- Presentations at ADA 2026 in New Orleans, June 5-8; posters available after event.
- CEO notes DA-1726 potential as differentiated obesity treatment; vanoglipel broad liver/metabolic therapeutic potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/0001104659-26-063059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/mtva-20260518x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-063059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer